Hikma Announces Expanded Licensing Agreement with Takeda

Hikma Pharmaceuticals has reached an agreement with Takeda Pharmaceutical to expand its licensing and distribution agreement adding new products to its portfolio in the Middle East and North Africa (MENA). Hikma will have the right to register, manufacture, market, distribute and sell four of Takeda's primary care products in 17 markets in the MENA region.

Under the terms of the agreement, which is effective immediately for all markets, Hikma has the exclusive rights to manufacture and commercialize three of Takeda's primary care product families - Alogliptin, including Alogliptin/Metformin, Alogliptin/Pioglitazone (anti-diabetic), Azilsartan, including Azilsartan/Chlorothalidone (anti-hypertensive) and Lornoxicam in its rapid form (anti-inflammatory/ pain) - in its MENA markets. The agreement, however, does not include the Egyptian market for Alogloptin. Hikma also has exclusive rights to manufacture and commercialize Takeda's Dexlansoprozole in its MENA markets, with the exception of Saudi Arabia, the UAE and Egypt. Hikma's existing license agreement with Takeda in respect of Lornoxicam tablets (anti-inflammatory/ pain), has been expanded beyond Saudi Arabia and Jordan to cover Hikma's other MENA markets.

"Our large sales and marketing teams, with particular expertise in promoting cardiovascular and diabetes treatments, are well positioned to drive strong demand for Takeda's products," Mazen Darwazah, Executive Vice Chairman and CEO of MENA and Emerging Markets said. "We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region. By working with global partners we are strengthening our product portfolio in growing therapeutic areas and reinforcing our commitment to improving patient access to quality medicines."